Utilization of targeted agents in all lines of therapy
| Agent . | Front line (n = 3771) . | Second line (n = 1728) . | Third line (n = 822) . | Fourth line (n = 389) . | Fifth line and greater (n = 330) . |
|---|---|---|---|---|---|
| BTK inhibitors ± chemoimmunotherapy | 151 (4%) | 647 (37%) | 330 (40%) | 118 (30%) | 78 (24%) |
| Bortezomib ± chemoimmunotherapy | 148 (4%) | 120 (7%) | 89 (11%) | 47 (12%) | 35 (10%) |
| Lenalidomide ± chemoimmunotherapy | 73 (2%) | 67 (4%) | 58 (7%) | 44 (11%) | 45 (13%) |
| Venetoclax ± chemoimmunotherapy | 3 (0%*) | 7 (0%*) | 21 (3%) | 19 (5%) | 34 (10%) |
| Venetoclax + BTK inhibitors | 0 (0%) | 8 (0%*) | 28 (3%) | 11 (3%) | 8 (2%) |
| Bendamustine + rituximab | 1576 (42%) | 262(15%) | 66 (8%) | 44 (11%) | 18 (5%) |
| R-CHOP | 643 (17%) | 67 (4%) | 21 (3%) | 7 (2%) | 3 (1%) |
| HyperCVAD | 266 (7%) | 22 (1%) | 9 (1%) | 5 (1%) | 5 (1%) |
| R-CHOP/R-DHAP | 60 (2%) | 13 (1%) | 4 (0%*) | 0 (0%*) | 0 (0%*) |
| BR/HiDAC | 24 (1%) | 5 (0%*) | 2 (0%*) | 0 (0%*) | 2 (1%) |
| Rituximab monotherapy | 292 (8%) | 131 (8%) | 44 (5%) | 8 (2%) | 13 (4%) |
| Other cytarabine-containing chemotherapy | 161 (4%) | 122 (7%) | 13 (2%) | 7 (2%) | 7 (2%) |
| Other chemotherapy† | 374 (10%) | 257 (15%) | 152 (18%) | 92 (23%) | 94 (28%) |
| Agent . | Front line (n = 3771) . | Second line (n = 1728) . | Third line (n = 822) . | Fourth line (n = 389) . | Fifth line and greater (n = 330) . |
|---|---|---|---|---|---|
| BTK inhibitors ± chemoimmunotherapy | 151 (4%) | 647 (37%) | 330 (40%) | 118 (30%) | 78 (24%) |
| Bortezomib ± chemoimmunotherapy | 148 (4%) | 120 (7%) | 89 (11%) | 47 (12%) | 35 (10%) |
| Lenalidomide ± chemoimmunotherapy | 73 (2%) | 67 (4%) | 58 (7%) | 44 (11%) | 45 (13%) |
| Venetoclax ± chemoimmunotherapy | 3 (0%*) | 7 (0%*) | 21 (3%) | 19 (5%) | 34 (10%) |
| Venetoclax + BTK inhibitors | 0 (0%) | 8 (0%*) | 28 (3%) | 11 (3%) | 8 (2%) |
| Bendamustine + rituximab | 1576 (42%) | 262(15%) | 66 (8%) | 44 (11%) | 18 (5%) |
| R-CHOP | 643 (17%) | 67 (4%) | 21 (3%) | 7 (2%) | 3 (1%) |
| HyperCVAD | 266 (7%) | 22 (1%) | 9 (1%) | 5 (1%) | 5 (1%) |
| R-CHOP/R-DHAP | 60 (2%) | 13 (1%) | 4 (0%*) | 0 (0%*) | 0 (0%*) |
| BR/HiDAC | 24 (1%) | 5 (0%*) | 2 (0%*) | 0 (0%*) | 2 (1%) |
| Rituximab monotherapy | 292 (8%) | 131 (8%) | 44 (5%) | 8 (2%) | 13 (4%) |
| Other cytarabine-containing chemotherapy | 161 (4%) | 122 (7%) | 13 (2%) | 7 (2%) | 7 (2%) |
| Other chemotherapy† | 374 (10%) | 257 (15%) | 152 (18%) | 92 (23%) | 94 (28%) |